/ALNY
Alnylam Pharmaceuticals, Inc.
ALNY • NASDAQALNY • NASDAQ • Healthcare
$313.41-1.20%-3.82
$313.41-1.20%(-3.82)Healthcare
GoAI Score
Sign in to unlock
Valuation
50Fair Value
Sentiment
100Bullish
Risk
100Low Risk
Momentum
6Negative
Institutional-Grade Intelligence
🏆PRO
Actionable Intelligence
AI-driven stance, execution logic & risk thresholds
Catalyst Roadmap
Event timeline with expected impact & market context
Deep Insights
Fact-checked analysis & score logic breakdown
Financial Statements
Margin Trends
Gross
81.8%▼3.8pp
Revenue after COGS
Operating
13.5%▲21.4pp
After operating expenses
Net
8.4%▲20.8pp
Bottom-line profitability
Gross Margin
Operating Margin
Net Margin
Valuation Snapshot
P/E Ratio
166.0
Price vs earnings
EV/EBITDA
92.8
Enterprise value
FCF Yield
0.9%
Cash generation
Earnings Yield
0.6%
Inverse of P/E
Capital Efficiency
20
GoAI Quality ScoreStrong
ROEReturn on Equity
39.8%Strong
ROAReturn on Assets
6.3%Strong
ROICReturn on Invested Capital
13.7%Strong
Financial Health
Current RatioHealthy
2.76
Short-term solvency (>1.5)
Net Debt / EBITDANet Cash
-0.68x
Debt repayment capacity (<3x)
Income QualityStrong
1.67
Cash backs earnings (>1)
Revenue & Profitability
Revenue
Net Income
Net Loss
Income Statement
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | $3.71B | $2.25B | $1.83B | $1.04B | $844.29M |
| Gross Profit | $3.04B | $1.92B | $1.52B | $868.60M | $704.14M |
| Gross Margin | 81.8% | 85.6% | 83.0% | 83.7% | 83.4% |
| Operating Income | $501.58M | -$176.88M | -$282.18M | -$785.07M | -$708.65M |
| Net Income | $313.75M | -$278.16M | -$440.24M | -$1.13B | -$852.82M |
| Net Margin | 8.4% | -12.4% | -24.1% | -109.0% | -101.0% |
| EPS | $2.39 | -$2.18 | -$3.52 | -$9.30 | -$7.20 |
Average Price Target
$460.50▲ 46.9% Upside
Past 12 Months
12 Month Forecast
Based on 50 Wall Street analysts offering 12 month price targets for Alnylam Pharmaceuticals, Inc., the average price target is $460.50, with a high forecast of $549.00 and a low forecast of $351.00. The average price target represents a 46.9% increase from the current price of $313.41.
Highest
$549.00
Average
$460.50
Lowest
$351.00
Rating Distribution
Strong Buy
0
0%
Buy
39
76%
Hold
11
22%
Sell
1
2%
Strong Sell
0
0%
Recent Analyst Ratings
FirmActionRatingDate
HC Wainwright & Co.● Maintain
Buy
2026-02-18Freedom Capital Markets▲ Upgrade
Hold→Buy
2026-02-17Canaccord Genuity● Maintain
Buy
2026-02-17Chardan Capital● Maintain
Buy
2026-02-13Needham● Maintain
Buy
2026-02-12B of A Securities● Maintain
Buy
2026-01-30HC Wainwright & Co.● Maintain
Buy
2026-01-30Morgan Stanley● Maintain
Equal Weight
2026-01-30Wells Fargo● Maintain
Equal Weight
2026-01-20RBC Capital● Maintain
Outperform
2026-01-20Earnings History & Surprises
BEAT RATE
67%
Last 18 quarters
AVG SURPRISE
+61.5%
EPS vs Estimate
BEATS / MISSES
12/6
Last 18 quarters
LATEST EPS
$1.25
Q1 '26
QUARTERLY EPS TREND
Estimated
Beat
Miss
QUARTERLY DETAIL
Q1 '26
+7.8%
$1.25 vs $1.16
Q4 '25
+416.9%
$2.90 vs $0.56
Q3 '25
+158.9%
$0.32 vs $-0.54
Q2 '25
+98.9%
$-0.01 vs $-0.89
Q1 '25
+109.7%
$0.06 vs $-0.62
Q4 '24
+45.5%
$-0.50 vs $-0.92
Q3 '24
+152.3%
$0.56 vs $-1.07
Q2 '24
+85.7%
$-0.16 vs $-1.12
Q1 '24
+8.3%
$-1.10 vs $-1.20
Q4 '23
+185.8%
$1.15 vs $-1.34
Q3 '23
-28.5%
$-2.21 vs $-1.72
Q2 '23
+28.9%
$-1.40 vs $-1.97
No investor questions available.
Latest News
No news available